MedTrace Logo

Preliminary Administration of EPO and Markers of Cardiac Ischemia Induced by CPB

NCT00273767 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 50

Last updated 2009-12-07

No results posted yet for this study

Summary

The main objective is to observe the effects of erythropoietin administration on different blood markers of ischaemic cardiac lesions induced by cardiopulmonary bypass.

Conditions

  • Myocardial Ischemia

Interventions

DRUG

epoetin beta

800UI/kg in 60ml of Nacl IV slow 1 to 3 hours before surgery

DRUG

placebo

60ml of NaCl IV slow

Sponsors & Collaborators

  • Roche Pharma AG

    collaborator INDUSTRY

  • University Hospital, Grenoble

    lead OTHER

Principal Investigators

  • Olivier CHAVANON, Pr · Institut National de la Santé Et de la Recherche Médicale, France

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-01-31
Primary Completion
2009-07-31
Completion
2009-11-30

Countries

  • France

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00273767 on ClinicalTrials.gov